A BILL 
To amend the Federal Food, Drug, and Cosmetic Act and 
the Securities Exchange Act of 1934 to prevent the 
inter partes review process for challenging patents from 
diminishing competition in the pharmaceutical industry 
and with respect to drug innovation, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Hatch-Waxman Integ-
4
rity Act of 2019’’. 
5
02:01 Feb 15, 2019
H990
2 
•HR 990 IH
SEC. 2. PREVENTING THE INTER PARTES REVIEW PROCESS 
1
FOR CHALLENGING PATENTS FROM DIMIN-
2
ISHING 
COMPETITION 
IN 
THE 
PHARMA-
3
CEUTICAL INDUSTRY AND WITH RESPECT TO 
4
DRUG INNOVATION. 
5
(a) BRAND NAME DRUGS.—Section 505(b)(2) of the 
6
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
7
355(b)(2)) is amended— 
8
(1) in subparagraph (A)(iv), by striking ‘‘and’’ 
9
at the end; 
10
(2) in subparagraph (B), by striking the period 
11
at the end and inserting ‘‘; and’’; and 
12
(3) by adding at the end the following: 
13
‘‘(C) in each certification required under sub-
14
paragraph (A) with respect to a patent, a certifi-
15
cation that— 
16
‘‘(i) neither the applicant nor any party in 
17
privity with, related to, or cooperating with the 
18
applicant has filed, or will file, a petition to in-
19
stitute inter partes review or post-grant review 
20
of that patent under chapter 31 or 32, respec-
21
tively, of title 35, United States Code; and 
22
‘‘(ii) in making the certification required 
23
under subparagraph (A), the applicant is not 
24
relying in whole or in part on any decision 
25
issued by the Patent Trial and Appeal Board in 
26
02:01 Feb 15, 2019
H990
3 
•HR 990 IH
an inter partes review or post-grant review 
1
under chapter 31 or 32, respectively, of title 35, 
2
United States Code.’’. 
3
(b) GENERIC DRUGS.—Section 505(j)(2)(A) of the 
4
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
5
355(j)(2)(A)) is amended— 
6
(1) in clause (vii)(IV), by striking ‘‘and’’ at the 
7
end; 
8
(2) in clause (viii), by striking the period at the 
9
end and inserting ‘‘; and’’; 
10
(3) by inserting after clause (viii), as amended 
11
by paragraph (2), the following: 
12
‘‘(ix) in each certification required under 
13
clause (vii) with respect to a patent, a certifi-
14
cation that— 
15
‘‘(I) neither the applicant nor any 
16
party in privity with, related to, or cooper-
17
ating with the applicant has filed, or will 
18
file, a petition to institute inter partes re-
19
view or post-grant review of that patent 
20
under chapter 31 or 32, respectively, of 
21
title 35, United States Code; and 
22
‘‘(II) in making the certification re-
23
quired under clause (vii), the applicant is 
24
not relying in whole or in part on any deci-
25
02:01 Feb 15, 2019
H990
4 
•HR 990 IH
sion issued by the Patent Trial and Appeal 
1
Board in an inter partes review or post- 
2
grant review under chapter 31 or 32, re-
3
spectively, of title 35, United States 
4
Code.’’; and 
5
(4) in the flush text following clause (ix), as 
6
added by paragraph (3), by striking ‘‘(viii)’’ and in-
7
serting ‘‘(ix)’’. 
8
(c) BIOSIMILAR DRUGS; EVALUATION BY THE SEC-
9
RETARY.—Section 351(k) of the Public Health Service Act 
10
(42 U.S.C. 262(k)) is amended— 
11
(1) in paragraph (2)(A)(iii)— 
12
(A) by redesignating subclauses (I) and 
13
(II) as items (aa) and (bb), respectively, and 
14
adjusting the margins accordingly; 
15
(B) in the matter preceding item (aa), as 
16
so redesignated, by striking ‘‘An application’’ 
17
and inserting the following: 
18
‘‘(I) IN GENERAL.—An application’’; 
19
(C) in subclause (I), as so designated— 
20
(i) in item (aa), as so redesignated, by 
21
striking ‘‘and’’ at the end; 
22
(ii) in item (bb), as so redesignated, 
23
by striking the period at the end and in-
24
serting ‘‘; and’’; and 
25
02:01 Feb 15, 2019
H990
5 
•HR 990 IH
(iii) by adding at the end the fol-
1
lowing: 
2
‘‘(cc) shall, with respect to a 
3
patent described in subclause 
4
(II), include a certification that 
5
neither the applicant nor any 
6
party in privity with, related to, 
7
or cooperating with the applicant 
8
has filed, or will file, a petition to 
9
institute inter partes review or 
10
post-grant review of the patent 
11
under chapter 31 or 32, respec-
12
tively, of title 35, United States 
13
Code.’’; and 
14
(D) by adding at the end the following: 
15
‘‘(II) PATENT
DESCRIBED.—A 
16
patent is described in this subclause 
17
if— 
18
‘‘(aa) the patent covers the 
19
reference product or a method 
20
for using the reference product; 
21
and 
22
‘‘(bb)(AA) 
the 
reference 
23
product described in item (aa) is 
24
02:01 Feb 15, 2019
H990
6 
•HR 990 IH
marked under section 287(a) of 
1
title 35, United States Code; or 
2
‘‘(BB) there is otherwise 
3
public notice regarding the appli-
4
cability of the reference product 
5
described in item (aa).’’; and 
6
(2) in paragraph (3)— 
7
(A) in subparagraph (A)(ii), by striking 
8
‘‘and’’ at the end; 
9
(B) in subparagraph (B), by striking the 
10
period at the end and inserting ‘‘; and’’; and 
11
(C) by adding at the end the following: 
12
‘‘(C) the Secretary determines that the ap-
13
plication fully complies with the requirements 
14
under paragraph (2)(A)(iii).’’. 
15
SEC. 3. PREVENTING THE MANIPULATIVE AND DECEPTIVE 
16
USE OF INTER PARTES REVIEW. 
17
Section 10(b) of the Securities Exchange Act of 1934 
18
(15 U.S.C. 78j(b)) is amended— 
19
(1) by inserting ‘‘(1)’’ after ‘‘(b)’’; and 
20
(2) by adding at the end the following: 
21
‘‘(2) For purposes of paragraph (1), a person shall 
22
be considered to be using a manipulative or deceptive de-
23
vice if— 
24
02:01 Feb 15, 2019
H990
7 
•HR 990 IH
‘‘(A) the person, or an affiliate of the person, 
1
files a petition to institute an inter partes review 
2
under chapter 31 of title 35, United States Code, 
3
with respect to a patent; and 
4
‘‘(B) the person, or an affiliate of the person, 
5
during the 180-day period beginning on the date 
6
that is 90 days before the date on which the person 
7
files the petition described in subparagraph (A), en-
8
gages in a short sale of any publicly traded security 
9
of the owner of the patent that is the subject of the 
10
petition.’’. 
11
Æ 
02:01 Feb 15, 2019
H990
